May. 10 at 4:40 PM
$ACAD great analysis from @Night_Owl_Biotech
my updated thesis for acadia.
fdmc:
$4.25B (
$22.50/sh)
cash:
$850M
catalysts: Remlifanserin (ADP): Top-line Phase 2 RADIANT study results expected August–October 2026.
Executive Summary
-- ACADIA is evolving into a high-growth commercial powerhouse, anchored by NUPLAZID (PDP) and DAYBUE (Rett syndrome). The thesis has shifted toward a "spend-to-grow" model, characterized by aggressive SG&A investment (up 35% YoY) to secure market dominance in Rett syndrome ahead of potential gene therapy competitors. The near-term value is heavily tied to the high-stakes remlifanserin readout in ADP.
Financials
-- Fully Diluted Share Count: ~190.11 million (Updated as of April 29, 2026; includes 171.24M basic shares plus ~18.9M in options/awards).
-- Fully Diluted Market Cap (at
$22.50/share): ~
$4.28 billion.
-- Cash and Equivalents:
$851.5 million (Actual as of March 31, 2026).
-- Pro Forma Cash (May 1): ~
$862.7 million (Calculated as
$851.4M as of March 31, plus an estimated
$11.3M in net cash generated during April).
-- Net Cash from Ops: Notably, net cash provided by operating activities actually improved to
$33.9M in Q1 (vs.
$20.3M in Q1 2025), showing that current revenue is absorbing the increased SG&A load better than expected.
Commercial Portfolio & Pipeline
-- NUPLAZID (pimavanserin): Commercial stage. Strong Q1 unit growth; GAAP net sales of
$166.9M. Primary risk is the 2026 patent trial regarding the 34mg formulation.
-- DAYBUE (trofinetide): Commercial stage. GAAP net sales of
$101.1M (up 20% YoY). Launch of DAYBUE STIX is the current growth engine; 30% of STIX patients are new/returning.
-- Remlifanserin (ACP-204): Phase 2/3. Expanded to include Lewy Body Dementia Psychosis (LBDP) as of Sept 2025. This asset is now the central "make-or-break" pipeline driver.
-- ACP-211: Phase 2. Initiated for Major Depressive Disorder (MDD) in Q4 2025.
-- ACP-711: Phase 2 ready. MOA: Selective GABAA-α3 PAM for Essential Tremor.
-- ACP-271: Phase 1. GPR88 agonist; first-in-human study initiated Q1 2026.
Catalyst Readout Timeline
-- Trofinetide (EU Re-examination): Decision on CHMP trend vote expected Q3 2026.
-- Remlifanserin (ADP) RADIANT Study: Top-line results confirmed for August–October 2026.
-- Trofinetide (Japan): Readout accelerated to September–November 2026.
-- Zydus Patent Trial (34mg NUPLAZID): Commencing November 2, 2026.
Competition and Competitive Positioning
-- PDP Market: NUPLAZID remains the only FDA-approved therapy. It competes primarily with off-label generic antipsychotics (quetiapine, clozapine). Its key advantage is a lack of dopamine receptor (D2) blockade, which avoids the motor-function deterioration common with generic alternatives.
-- ADP Market (Pipeline): Remlifanserin (ACP-204) is positioned to address a massive unmet need with no approved therapies. The RADIANT study (Phase 2) is on a similar timeline to Cobenfy's ADEPT trials (BMS), but Acadia's serotonergic MOA may offer a more favorable gastrointestinal and safety profile for elderly patients compared to muscarinic agonists.
-- Muscarinic Competition: Cobenfy (KarXT) and Emraclidine (AbbVie/Cerevel) represent the primary "next-gen" threats. While Cobenfy is already approved for Schizophrenia, its entry into ADP depends on late-2026 readouts. Acadia maintains that 5-HT2A antagonism remains the preferred MOA to avoid the cognitive decline and cholinergic side effects (nausea/vomiting) linked to muscarinic agents in AD populations.
-- Rett Syndrome Market: DAYBUE is the first and only approved treatment. While it faces emerging gene therapy threats from Taysha (TSHA-102) and Neurogene (NGN-401), these remain in mid-stage development. Acadia is defending its lead through the launch of DAYBUE STIX, providing flexible dosing and improved taste to increase persistency over potential competitors.
-- Essential Tremor: ACP-711 is entering a crowded field of generic beta-blockers and anticonvulsants. Its competitive edge lies in its GABAA-α3 selectivity, designed to provide efficacy without the sedation and "brain fog" associated with standard-of-care treatments like primidone.
Executive Team and Board (BOD)
-- CEO: Catherine Owen Adams (formerly Bristol Myers Squibb), brought in for her deep commercial launch expertise.
-- CFO: Mark Schneyer, leading the transition to sustained profitability.
-- Board Chair: Stephen R. Biggar, M.D., Ph.D. (Partner at Baker Bros. Advisors).
-- Key Board Members: Julian Baker (Baker Bros. Advisors) and veteran biopharma executives from Pfizer, Vertex, and Novartis. Significant oversight by Baker Bros. (~25% ownership).
Bull Thesis
-- Operating leverage: The 35% SG&A hike is front-loaded; success in the ADP trial would allow Acadia to plug a new multi-billion dollar indication into an already-scaled sales infrastructure.
-- Strong unit growth in both franchises despite IRA pricing pressures.
--
$851M cash pile provides a massive buffer to fund the pipeline through 2027 without dilution.
Bear Thesis
-- Operating Loss: The company swung to a
$4.6M operating loss in Q1 2026. Profits are currently dependent on interest income from the cash pile.
-- Binary Risk: Failure of the RADIANT study would likely lead to a significant re-rating of the stock toward a "legacy commercial" valuation.
-- Legal Overhang: The Zydus patent trial (Nov 2026) and the ongoing City of Birmingham class action create long-term liability and exclusivity uncertainty.
